Selective androgen receptor modulators: In vitro and in vivo metabolism and analysis

Food Additives and Contaminants - Part A

Volumn 30, Issue 9, 2013, Pages 1517-1526

  de Rijke, Eva ^a   Essers, Martien L ^a   Rijk, Jeroen C W ^a   Thevis, Mario ^b   Bovee, Toine F H ^a   van Ginkel, Leendert A ^a   Sterk, Saskia S ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

mass spectrometry; metabolism; selective androgen receptor modulator; ultra performance liquid chromatography; validation

Indexed keywords

ARSENIC COMPOUNDS; BIOMOLECULES; CARBOXYLATION; CELL CULTURE; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; METABOLISM; MODULATORS;

ANDROGEN RECEPTORS; COMMISSION DECISION 2002/657/EC; DETECTION CAPABILITY; RELATIVE STANDARD DEVIATIONS; TIME OF FLIGHT MASS SPECTROMETRY; TRIPLE-QUADRUPOLE MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION;

METABOLITES;

ANDARINE; ARYLPROPIONAMIDE 1; ARYLPROPIONAMIDE 2; BICALUTAMIDE; ENOBOSARM; LIVER ENZYME; NITROREDUCTASE; QUINOLINONE 1; QUINOLINONE 2; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARBOXYLATION; DEMETHYLATION; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; SOLID PHASE EXTRACTION; SULFATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

BOVINAE;

ACETANILIDES; AMIDES; ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; ANIMALS; CATTLE; CELL LINE; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; DRUGS, INVESTIGATIONAL; HUMANS; LACTATES; LIMIT OF DETECTION; MALE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MICROSOMES, LIVER; NITRILES; NONSTEROIDAL ANTI-ANDROGENS; QUINOLONES; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TOSYL COMPOUNDS; VETERINARY DRUGS;

EID: 84883488821     PISSN: 19440049     EISSN: 14645122     Source Type: Journal    
DOI: 10.1080/19440049.2013.810346     Document Type: Article

References (15)

1. Bovee TFH, Thevis M, Hamers ARM, Peijnenburg AACM, Nielen MWF, Schoonen WGEJ. 2010. SERMs and SARMs: detection of their activities with yeast based bioassays, J Steroid Biochem Mol Biol. 118:85-92.
2. CRL Guidance Paper. 2007. CRLs view on state of the art analytical methods for national residue control plans. Available from: http://crl.fougeres.anses.fr/publicdoc/2013/EURL_Guidance_Concentrations_Minimales_Recommend%C3%A9es_Methodes_Analytiques.pdf
3. European Commission. 2002. Commission Decision 2002/657/EC implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. [cited 2012 Sep]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2002:221:0008:0036:EN:PDF
4. Gao W, Dalton JT. 2007. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today. 12:241-248.
5. Grata E, Perrenoud L, Saugy M, Baume N. 2011. SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci Int. 213:104-108.
6. Kuuranne T, Leinonen A, Schänzer W, Kamber M, Kostiainen R, Thevis M. 2008. Arylpropionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in-vitro synthesized metabolites for doping control purposes. Drug Metab Dispos. 36:571-581.
7. Rijk JCW, Bovee TFH, Groot MJ, Peijnenburg AAC, Nielen MWF. 2008. Evidence of the indirect hormonal activity of prohormones using liver S9 metabolic bioactivation and an androgen bioassay. Anal Bioanal Chem. 392:417-425.
8. Segal S, Narayanan R, Dalton JT. 2006. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs. 15:377-387.
9. Thevis M, Geyer H, Kamber M, Schänzer W. 2009. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test Anal. 1:387-392.
10. Thevis M, Kamber M, Schänzer W. 2006. Screening for metabolically stable arylpropionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun Mass Spectrom. 20:870-876.
11. Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W. 2007. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. Rapid Commun Mass Spectrom. 21:3477-3486.
12. Thevis M, Schänzer W. 2008. Mass spectrometry of selective androgen receptor modulators. J Mass Spectrom. 43:865-876.
13. Thevis M, Thomas A, Fußhöller G, Beuck S, Geyer H, Schänzer W. 2010. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. Rapid Commun Mass Spectrom. 24:2245-2254.
14. Thevis M, Thomas A, Möller I, Geyer H, Dalton JT, Schänzer W. 2011. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. Rapid Commun Mass Spectrom. 25:2187-2195.
15. World Anti-Doping Agency. 2012. Available from: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_Prohibited_List_2012_EN.pdf